Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Clinical Characteristics in Patients with Triple Negative Breast Cancer.

Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, Axelrod D, Shapiro R, Schnabel F.

Int J Breast Cancer. 2017;2017:1796145. doi: 10.1155/2017/1796145. Epub 2017 Aug 17.

2.

Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women.

Bassey-Archibong BI, Hercules SM, Rayner LGA, Skeete DHA, Smith Connell SP, Brain I, Daramola A, Banjo AAF, Byun JS, Gardner K, Dushoff J, Daniel JM.

Cancer Causes Control. 2017 Nov;28(11):1295-1304. doi: 10.1007/s10552-017-0955-2. Epub 2017 Sep 8.

3.

Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.

Sandhu GS, Erqou S, Patterson H, Mathew A.

J Glob Oncol. 2016 Jun 29;2(6):412-421. doi: 10.1200/JGO.2016.005397. eCollection 2016 Dec. Review.

4.

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.

Ocana A, Pandiella A.

Oncotarget. 2017 Mar 28;8(13):22218-22234. doi: 10.18632/oncotarget.14731. Review.

5.

Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.

Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L.

Breast Cancer Res. 2017 Jan 13;19(1):6. doi: 10.1186/s13058-016-0799-9.

6.
7.

Novel therapeutic strategies for patients with triple-negative breast cancer.

Zhang JF, Liu J, Wang Y, Zhang B.

Onco Targets Ther. 2016 Oct 21;9:6519-6528. eCollection 2016. Review.

8.

Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database.

Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR.

Medicine (Baltimore). 2016 Aug;95(35):e4614. doi: 10.1097/MD.0000000000004614.

9.

Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Stewart DA, Winnike JH, McRitchie SL, Clark RF, Pathmasiri WW, Sumner SJ.

J Proteome Res. 2016 Sep 2;15(9):3225-40. doi: 10.1021/acs.jproteome.6b00430. Epub 2016 Aug 3.

10.

Integration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis.

Ziegler YS, Moresco JJ, Yates JR 3rd, Nardulli AM.

PLoS One. 2016 Jun 29;11(6):e0158296. doi: 10.1371/journal.pone.0158296. eCollection 2016.

11.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

12.

Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.

Robles AJ, Cai S, Cichewicz RH, Mooberry SL.

Breast Cancer Res Treat. 2016 Jun;157(3):475-88. doi: 10.1007/s10549-016-3841-9. Epub 2016 Jun 2.

13.

Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.

Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, Li CI.

Breast Cancer Res Treat. 2016 Jun;157(3):545-54. doi: 10.1007/s10549-016-3825-9. Epub 2016 May 24.

14.

Breed- and age-related differences in canine mammary tumors.

Kim HW, Lim HY, Shin JI, Seung BJ, Ju JH, Sur JH.

Can J Vet Res. 2016 Apr;80(2):146-55.

15.

Expression of Intratumoral IGF-II Is Regulated by the Gene Imprinting Status in Triple Negative Breast Cancer from Vietnamese Patients.

Radhakrishnan VK, Hernandez LC, Anderson K, Tan Q, De León M, De León DD.

Int J Endocrinol. 2015;2015:401851. doi: 10.1155/2015/401851. Epub 2015 Sep 10.

16.

Mammography Adherence in African-American Women: Results of a Randomized Controlled Trial.

Gathirua-Mwangi WG, Monahan PO, Stump T, Rawl SM, Skinner CS, Champion VL.

Ann Behav Med. 2016 Feb;50(1):70-8. doi: 10.1007/s12160-015-9733-0.

17.

Socioeconomic status and incidence of breast cancer by hormone receptor subtype.

Akinyemiju TF, Pisu M, Waterbor JW, Altekruse SF.

Springerplus. 2015 Sep 17;4:508. doi: 10.1186/s40064-015-1282-2. eCollection 2015.

18.

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes.

Parise CA, Caggiano V.

J Cancer Epidemiol. 2015;2015:813456. doi: 10.1155/2015/813456. Epub 2015 Aug 3.

19.

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Lehmann BD, Pietenpol JA.

Breast. 2015 Nov;24 Suppl 2:S36-40. doi: 10.1016/j.breast.2015.07.009. Epub 2015 Aug 5. Review.

20.

Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.

Vaca-Paniagua F, Alvarez-Gomez RM, Maldonado-Martínez HA, Pérez-Plasencia C, Fragoso-Ontiveros V, Lasa-Gonsebatt F, Herrera LA, Cantú D, Bargallo-Rocha E, Mohar A, Durand G, Forey N, Voegele C, Vallée M, Le Calvez-Kelm F, McKay J, Ardin M, Villar S, Zavadil J, Olivier M.

PLoS One. 2015 May 11;10(5):e0126762. doi: 10.1371/journal.pone.0126762. eCollection 2015.

Supplemental Content

Support Center